EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming

34Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The molecular mechanisms driving metastatic progression in triple-negative breast cancer (TNBC) patients are poorly understood. In this study, we demonstrate that epidermal growth factor-like 9 (EGFL9) is significantly upregulated in basal-like breast cancer cells and associated with metastatic progression in breast tumor samples. Functionally, EGFL9 is both necessary and sufficient to enhance cancer cell migration and invasion, as well as distant metastasis. Mechanistically, we demonstrate that EGFL9 binds cMET, activating cMET-mediated downstream signaling. EGFL9 and cMET co-localize at both the cell membrane and within the mitochondria. We further identify an interaction between EGFL9 and the cytochrome c oxidase (COX) assembly factor COA3. Consequently, EGFL9 regulates COX activity and modulates cell metabolism, promoting a Warburg-like metabolic phenotype. Finally, we show that combined pharmacological inhibition of cMET and glycolysis reverses EGFL9-driven stemness. Our results identify EGFL9 as a therapeutic target for combating metastatic progression in TNBC.

Cite

CITATION STYLE

APA

Meng, F., Wu, L., Dong, L., Mitchell, A. V., James Block, C., Liu, J., … Wu, G. (2019). EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-13034-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free